ANAB vs SOPH: fair value comparison
AnaptysBio, Inc. and SOPHiA GENETICS SA · Updated 2026-10-19
ANAB's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. SOPH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SOPH currently ranks higher by quality score. SOPH carries the stronger quality grade.
| ANAB | SOPH | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $46.61 | $6.73 |
| 12-month range | $22.06–$69.81 | $3.89–$8.92 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #162 of 301 Healthcare | #160 of 301 Healthcare |
| Quality grade | F | D |
| Leverage | High | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ANAB fair value analysis · SOPH fair value analysis